{"groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"FG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"FG001","title":"Combination"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}